Evidence map›Paper›PMID 29435180›Full record

ArticleOncotarget2018

New cGMP analogues restrain proliferation and migration of melanoma cells.

Eleonora Vighi, Andreas Rentsch, Philipp Henning, Antonella Comitato, Dorit Hoffmann, Daniela Bertinetti, Evelina Bertolotti, Frank Schwede, Friedrich W Herberg, Hans-Gottfried Genieser and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. New In Vitro Cellular Model for Molecular Studies of Retinitis Pigmentosa.International journal of molecular sciences · 2021
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Eleonora VighiUniversity of Modena and Reggio Emilia, Department of Life Sciences, 41125 Modena, Italy.
Andreas RentschBIOLOG Life Science Institute Forschungslabor und Biochemica-Vertrieb GmbH, 28199 Bremen, Germany.
Philipp HenningDepartment of Biochemistry, University of Kassel, 34132 Kassel, Germany.
Antonella ComitatoUniversity of Modena and Reggio Emilia, Department of Life Sciences, 41125 Modena, Italy.
Dorit HoffmannUniversity of Modena and Reggio Emilia, Department of Life Sciences, 41125 Modena, Italy.
Daniela BertinettiDepartment of Biochemistry, University of Kassel, 34132 Kassel, Germany.
Evelina BertolottiUniversity of Modena and Reggio Emilia, Department of Life Sciences, 41125 Modena, Italy.
Frank SchwedeBIOLOG Life Science Institute Forschungslabor und Biochemica-Vertrieb GmbH, 28199 Bremen, Germany.
Friedrich W HerbergDepartment of Biochemistry, University of Kassel, 34132 Kassel, Germany.
Hans-Gottfried GenieserBIOLOG Life Science Institute Forschungslabor und Biochemica-Vertrieb GmbH, 28199 Bremen, Germany.
Valeria MarigoUniversity of Modena and Reggio Emilia, Department of Life Sciences, 41125 Modena, Italy.
University of Modena and Reggio Emilia · ITBiolog Life Science Institute · DEUniversity of Kassel · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is one of the most aggressive cancers and displays high resistance to conventional chemotherapy underlining the need for new therapeutic strategies. The cGMP/PKG signaling pathway was detected in melanoma cells and shown to reduce migration, proliferation and to increase apoptosis in different cancer types. In this study, we evaluated the effects on cell viability, cell death, proliferation and migration of novel dimeric cGMP analogues in two melanoma cell lines (MNT1 and SkMel28). These new dimeric cGMP analogues, by activating PKG with limited effects on PKA, significantly reduced proliferation, migration and increased cell death. No decrease in cell viability was observed in non-tumor cells suggesting a tumor-specific effect. These effects observed in melanoma are possibly mediated by PKG2 activation based on the decreased toxic effects in tumor cell lines not expressing PKG2. Finally, PKG-associated phosphorylation of vasodilator-stimulated-phosphoprotein (VASP), linked to cell death, proliferation and migration was found increased and with a change of subcellular localization. Increased phosphorylation of RhoA induced by activation of PKG may also contribute to reduced migration ability of the SkMel28 melanoma cell line when treated with cGMP analogues. These findings suggest that the cGMP/PKG pathway can be envisaged as a therapeutic target of novel dimeric cGMP analogues for the treatment of melanoma.

Indexed as

cGMPMNT1PKG2pVASPSkMel28

Identifiers

PMID29435180
PMCPMC5797051
OpenAlexW2776613323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.